GlobeNewswire: Onconova Therapeutics, Inc. Contains the last 10 of 275 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T11:57:56ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/08/2843074/0/en/Onconova-Therapeutics-Rigosertib-Poster-Selected-for-AACR-2024.html?f=22&fvtc=4&fvtv=26844Onconova Therapeutics’ Rigosertib Poster Selected for AACR 20242024-03-08T13:00:00Z<![CDATA[Translational science to characterize pathways impacted by rigosertib may help to guide future clinical studies and combination treatment regimen for difficult-to-treat cancers Translational science to characterize pathways impacted by rigosertib may help to guide future clinical studies and combination treatment regimen for difficult-to-treat cancers]]>https://www.globenewswire.com/news-release/2023/12/12/2794697/0/en/Onconova-Therapeutics-Narazaciclib-ASH-Poster-Highlights-Activity-in-Treatment-Resistant-Mantle-Cell-Lymphoma.html?f=22&fvtc=4&fvtv=26844Onconova Therapeutics’ Narazaciclib ASH Poster Highlights Activity in Treatment Resistant Mantle Cell Lymphoma2023-12-12T13:00:00Z<![CDATA[Preclinical data show that narazaciclib treatment led to significant tumor growth inhibition, demonstrating synergy with standard-of-care ibrutinib, in ibrutinib-sensitive and -resistant settings]]>https://www.globenewswire.com/news-release/2023/12/08/2793371/0/en/Onconova-Therapeutics-Preclinical-Narazaciclib-Data-at-SABCS-Highlights-Differentiated-Anti-Tumor-Activity-v-Other-CDK4-6i-s.html?f=22&fvtc=4&fvtv=26844Onconova Therapeutics’ Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i’s2023-12-08T21:05:00Z<![CDATA[Differentiated profile of narazaciclib supported by positive results of studies demonstrating broad multi-kinase activity, with significant anti-tumor activity and increased anti-tumor immunity, compared to approved CDK4/6 inhibitors]]>https://www.globenewswire.com/news-release/2023/11/28/2786864/0/en/Onconova-Therapeutics-to-Present-at-NobleCon19-Noble-Capital-Markets-Nineteenth-Annual-Emerging-Growth-Equity-Conference.html?f=22&fvtc=4&fvtv=26844Onconova Therapeutics to Present at NobleCon19, Noble Capital Markets’ Nineteenth Annual Emerging Growth Equity Conference2023-11-28T13:00:00Z<![CDATA[NEWTOWN, Pa., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”, the “Company”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that Steven Fruchtman, M.D., President & CEO, will present at NobleCon19, Noble Capital Markets’ Nineteenth Annual Emerging Growth Equity Conference, being held December 3-5, 2023 at Florida Atlantic University, Executive Education Complex, in Boca Raton, FL.]]>https://www.globenewswire.com/news-release/2023/11/14/2780492/0/en/Onconova-Therapeutics-Reports-Corporate-Update-and-Announces-Third-Quarter-2023-Financial-Results.html?f=22&fvtc=4&fvtv=26844Onconova Therapeutics Reports Corporate Update and Announces Third Quarter 2023 Financial Results2023-11-14T21:05:00Z<![CDATA[Narazaciclib progressing towards registrational studies; target engagement and acceptable safety profile support further dose escalation, affirming differentiated profile]]>https://www.globenewswire.com/news-release/2023/11/07/2775580/0/en/Onconova-Therapeutics-to-Provide-Corporate-Update-and-Announce-Third-Quarter-2023-Financial-Results-on-November-14-2023.html?f=22&fvtc=4&fvtv=26844Onconova Therapeutics to Provide Corporate Update and Announce Third Quarter 2023 Financial Results on November 14, 20232023-11-07T21:05:00Z<![CDATA[Company to host conference call and webcast at 4:30 p.m. ET on Tuesday, November 14, 2023 Company to host conference call and webcast at 4:30 p.m. ET on Tuesday, November 14, 2023]]>https://www.globenewswire.com/news-release/2023/11/02/2772556/0/en/Onconova-Therapeutics-ASH-Poster-To-Focus-on-Narazaciclib-in-MCL.html?f=22&fvtc=4&fvtv=26844Onconova Therapeutics’ ASH Poster To Focus on Narazaciclib in MCL2023-11-02T14:37:27Z<![CDATA[Preclinical data indicate that narazaciclib shows monotherapy and combination anti-tumor activity in ibrutinib-sensitive and resistant cells and xenograft models]]>https://www.globenewswire.com/news-release/2023/10/24/2765546/0/en/Onconova-Expands-Leadership-Team-with-Two-Key-Appointments.html?f=22&fvtc=4&fvtv=26844Onconova Expands Leadership Team with Two Key Appointments2023-10-24T12:00:00Z<![CDATA[Dr. Victor Moyo named Chief Medical OfficerMeena Arora joins as Vice President Global Medical Affairs and R&D]]>https://www.globenewswire.com/news-release/2023/10/19/2763141/0/en/Promising-Preclinical-Narazaciclib-Data-Presented-at-MCL-Meeting.html?f=22&fvtc=4&fvtv=26844Promising Preclinical Narazaciclib Data Presented at MCL Meeting2023-10-19T12:00:07Z<![CDATA[Data for Mantle cell lymphoma (MCL) presented in Ireland on Oct. 7, 2023Additional studies support broad potential, especially in cyclin-dependent cancers]]>https://www.globenewswire.com/news-release/2023/10/12/2759192/0/en/Encouraging-Rigosertib-Data-Presented-at-EADV-as-Late-Breaker.html?f=22&fvtc=4&fvtv=26844Encouraging Rigosertib Data Presented at EADV as Late Breaker2023-10-12T12:00:00Z<![CDATA[Reporting responses in patients with RDEB-associated SCC, a devastating disease with a significant unmet need Reporting responses in patients with RDEB-associated SCC, a devastating disease with a significant unmet need]]>